No apparent effect of naproxen on CSF markers of innate immune activation

We studied 78 participants having a parental or multiple‐sibling history of Alzheimer’s disease (AD) in a two‐year randomized placebo‐controlled trial of naproxen 220 mg b.i.d. for mitigation of early AD pathogenesis. Naproxen was detected in cerebrospinal fluid at concentrations ~100 times lower th...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Pierre‐François, Labonté, Anne, Rosa‐Neto, Pedro, Poirier, Judes, Breitner, John C. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562029/
https://www.ncbi.nlm.nih.gov/pubmed/31211178
http://dx.doi.org/10.1002/acn3.788
_version_ 1783426219541266432
author Meyer, Pierre‐François
Labonté, Anne
Rosa‐Neto, Pedro
Poirier, Judes
Breitner, John C. S.
author_facet Meyer, Pierre‐François
Labonté, Anne
Rosa‐Neto, Pedro
Poirier, Judes
Breitner, John C. S.
author_sort Meyer, Pierre‐François
collection PubMed
description We studied 78 participants having a parental or multiple‐sibling history of Alzheimer’s disease (AD) in a two‐year randomized placebo‐controlled trial of naproxen 220 mg b.i.d. for mitigation of early AD pathogenesis. Naproxen was detected in cerebrospinal fluid at concentrations ~100 times lower than in plasma, but produced negligible change in immune markers. The repeated lack of benefit in AD prevention trials using naproxen and related drugs may reflect limited CNS permeability, lack of expected drug effects, or both. These findings suggest reconsideration of implications from results of AD prevention trials using anti‐inflammatory drugs.
format Online
Article
Text
id pubmed-6562029
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65620292019-06-17 No apparent effect of naproxen on CSF markers of innate immune activation Meyer, Pierre‐François Labonté, Anne Rosa‐Neto, Pedro Poirier, Judes Breitner, John C. S. Ann Clin Transl Neurol Brief Communications We studied 78 participants having a parental or multiple‐sibling history of Alzheimer’s disease (AD) in a two‐year randomized placebo‐controlled trial of naproxen 220 mg b.i.d. for mitigation of early AD pathogenesis. Naproxen was detected in cerebrospinal fluid at concentrations ~100 times lower than in plasma, but produced negligible change in immune markers. The repeated lack of benefit in AD prevention trials using naproxen and related drugs may reflect limited CNS permeability, lack of expected drug effects, or both. These findings suggest reconsideration of implications from results of AD prevention trials using anti‐inflammatory drugs. John Wiley and Sons Inc. 2019-06-06 /pmc/articles/PMC6562029/ /pubmed/31211178 http://dx.doi.org/10.1002/acn3.788 Text en © 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Brief Communications
Meyer, Pierre‐François
Labonté, Anne
Rosa‐Neto, Pedro
Poirier, Judes
Breitner, John C. S.
No apparent effect of naproxen on CSF markers of innate immune activation
title No apparent effect of naproxen on CSF markers of innate immune activation
title_full No apparent effect of naproxen on CSF markers of innate immune activation
title_fullStr No apparent effect of naproxen on CSF markers of innate immune activation
title_full_unstemmed No apparent effect of naproxen on CSF markers of innate immune activation
title_short No apparent effect of naproxen on CSF markers of innate immune activation
title_sort no apparent effect of naproxen on csf markers of innate immune activation
topic Brief Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562029/
https://www.ncbi.nlm.nih.gov/pubmed/31211178
http://dx.doi.org/10.1002/acn3.788
work_keys_str_mv AT meyerpierrefrancois noapparenteffectofnaproxenoncsfmarkersofinnateimmuneactivation
AT labonteanne noapparenteffectofnaproxenoncsfmarkersofinnateimmuneactivation
AT rosanetopedro noapparenteffectofnaproxenoncsfmarkersofinnateimmuneactivation
AT poirierjudes noapparenteffectofnaproxenoncsfmarkersofinnateimmuneactivation
AT breitnerjohncs noapparenteffectofnaproxenoncsfmarkersofinnateimmuneactivation
AT noapparenteffectofnaproxenoncsfmarkersofinnateimmuneactivation

Ejemplares similares